MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
6407.31%
Quick Ratio
6407.31%
Cash Ratio
956.89%
Debt to Asset Ratio
1.66%
Unit: Thousand (K) dollars
Assets Breakdown
    • Marketable securities
    • Cash and cash equivalents
    • Prepaid expenses and other curre...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accumulated other comprehensive ...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
135,505
132,184
98,896
101,732
Marketable securities
759,650
320,217
363,725
375,833
Restricted cash
-
-
0
0
Prepaid expenses and other current assets
12,184
10,736
12,257
5,118
Total current assets
907,339
463,137
474,878
482,683
Property and equipment, net
140
20
34
399
Operating lease right-of-use assets
1,502
290
383
475
Deferred offering costs
0
217
217
217
Other long-term assets
1,242
1,188
656
7,101
Total assets
910,223
464,852
476,168
490,875
Accounts payable
371
1,640
2,159
1,429
Accrued expenses and other current liabilities
13,790
9,847
14,409
13,221
Total current liabilities
14,161
11,487
16,568
14,650
Long-term liabilities
913
-
-
103
Total liabilities
15,074
11,487
16,568
14,753
Common stock, par value 0.001 authorized shares - 200,000,000 and 100,000,000 at june 30, 2026 and december 31, 2025, respectively issued and outstanding shares - 73,251,648 and 59,440,045 at june 30, 2026 and december 31, 2025, respectively
73
61
59
59
Additional paid-in capital
1,300,259
824,479
806,373
793,341
Accumulated other comprehensive (loss) income
-1,905
-382
334
221
Accumulated deficit
-403,278
-370,793
-347,166
-317,499
Total stockholders' equity
895,149
453,365
459,600
476,122
Total liabilities and stockholders' equity
910,223
464,852
476,168
490,875
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities$759,650K (104.72%↑ Y/Y)Cash and cashequivalents$135,505K (13.45%↑ Y/Y)Prepaid expenses andother current assets$12,184K (138.02%↑ Y/Y)Total current assets$907,339K (83.07%↑ Y/Y)Operating leaseright-of-use assets$1,502K (166.31%↑ Y/Y)Other long-termassets$1,242K (-82.84%↓ Y/Y)Property and equipment,net$140K (-69.70%↓ Y/Y)Total assets$910,223K (80.64%↑ Y/Y)Total liabilities andstockholders' equity$910,223K (80.64%↑ Y/Y)Total stockholders'equity$895,149K (83.25%↑ Y/Y)Total liabilities$15,074K (-2.21%↓ Y/Y)Accumulated deficit-$403,278K (-35.62%↓ Y/Y)Accumulated othercomprehensive (loss) income-$1,905K (-976.27%↓ Y/Y)Additional paid-in capital$1,300,259K (65.44%↑ Y/Y)Total currentliabilities$14,161K (-6.90%↓ Y/Y)Long-term liabilities$913K (347.55%↑ Y/Y)Common stock, par value0.001 authorized...$73K (23.73%↑ Y/Y)Accrued expenses andother current...$13,790K (7.23%↑ Y/Y)Accounts payable$371K (-84.22%↓ Y/Y)

Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics, Inc. (ELVN)